Loading
Prelude Therapeutics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Bonita David P, was filed 23 Apr 2026.
Prelude Therapeutics Inc: what insiders have been doing
This page follows insider dealings at Prelude Therapeutics Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 22 October 2025 and 22 October 2026, 2 insiders published 3 filings.
Only purchases show up on the open market, 2 purchases in all worth €10.6M, filed by 1 insider. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive. Biggest ticket of the year: €6.4M, bought by Bonita David P and made public on 23 April 2026 (1.8% of market cap).
In the case of 2 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 23 April 2026, 183 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 3 filings, this issuer sits below that mark. Since 2020, the database holds 36 purchases and 67 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 12.1 m USD of revenue and -99.5 m USD of net income.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
177
Thresholds
n/a
Buy Volume
€62M
36 ops. · all time
Sell Volume
€9M
67 ops. · all time
Who traded when
BuySaleKrishna Vaddi11 buys
Andrew Combs3 buys
David P. Bonita2 buys
Bryant David Lim1 buy
Since the insiders bought
- -30.6%Entry US$4.70 · Close 16 Oct 2026 US$3.26
- +283.7%Entry US$0.80 · Close at T+365 US$3.07
- +283.7%Entry US$0.80 · Close at T+365 US$3.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Prelude Therapeutics Inc Strong Buy (bullish), based on 5 analysts. Average price target: US$9.20.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.40
Analyst consensus
5 analystsStrong buy
US$6.00Target US$9.20(+171%)US$12.00
Income statement
RevenueUS$12.1M
EBITDA-US$102.9M-847% margin
Net income-US$99.5M-269.7% margin
Valuation
PER (forward)-5.9x
P/Book2.6x
Beta0.96
Balance sheet & cash
Market capUS$270.8M
Total debtUS$17.8M
Free Cash Flow-US$56.4M
Debt / Equity13%
Profitability & ownership
ROE-57.7%
ROA-27.2%
% insiders13.8%
% institutions76.4%
Last declaration on 28 April 2026
Declarations177 total
1,407,000 sharesCommon StockSEC:0001231919-26-000422:0
1,689,189 shares@ US$4.441.84% mcap41.8% of flowCommon StockSEC:0000947871-26-000462:0
Canonical exit: 20 Jul 2026 (T+90)
1,126,126 shares@ US$4.441.23% mcap27.9% of flowCommon StockSEC:0000947871-26-000462:1
Canonical exit: 20 Jul 2026 (T+90)
1,689,189 shares@ US$4.441.84% mcap41.8% of flowCommon StockSEC:0000947871-26-000461:0
Canonical exit: 20 Jul 2026 (T+90)
1,126,126 shares@ US$4.441.23% mcap27.9% of flowCommon StockSEC:0000947871-26-000461:1
Canonical exit: 20 Jul 2026 (T+90)
3,355 shares@ US$1.472.9% of flowCommon StockSEC:0001683913-25-000004:1
9,375 sharesCommon StockSEC:0001683913-25-000004:0
3,355 shares@ US$0.79391.5% of flowCommon StockSEC:0001562180-25-005346:1
9,375 sharesCommon StockSEC:0001562180-25-005346:0
3,355 shares@ US$0.6751.4% of flowCommon StockSEC:0001562180-25-003036:1
9,375 sharesCommon StockSEC:0001562180-25-003036:0
100,000 shares@ US$0.692537.3% of flowCommon StockSEC:0001562180-25-002779:0
Canonical exit: 23 Jun 2025 (T+90)
675,000 shares@ US$0.692551.5% of flowCommon StockSEC:0001562180-25-002778:0
Canonical exit: 23 Jun 2025 (T+90)
15,000 shares@ US$0.73061.1% of flowCommon StockSEC:0001562180-25-002697:1
Canonical exit: 19 Jun 2025 (T+90)
5,416 shares@ US$0.72940.4% of flowCommon StockSEC:0001562180-25-002697:0
Canonical exit: 18 Jun 2025 (T+90)
9,106 shares@ US$0.74990.7% of flowCommon StockSEC:0001562180-25-002541:1
Canonical exit: 15 Jun 2025 (T+90)
29,999 shares@ US$0.75442.5% of flowCommon StockSEC:0001562180-25-002541:0
Canonical exit: 12 Jun 2025 (T+90)
50,000 shares@ US$0.71643.7% of flowCommon StockSEC:0001562180-25-002392:1
Canonical exit: 11 Jun 2025 (T+90)
47,500 shares@ US$0.71043.7% of flowCommon StockSEC:0001562180-25-002392:0
Canonical exit: 10 Jun 2025 (T+90)
3,859 shares@ US$1.393.6% of flowCommon StockSEC:0001562180-25-000237:1
9,375 sharesCommon StockSEC:0001562180-25-000237:0
5,000 shares@ US$1.20870.7% of flowCommon StockSEC:0001562180-25-000031:0
Canonical exit: 31 Mar 2025 (T+90)
10,000 shares@ US$1.201.4% of flowCommon StockSEC:0001562180-25-000008:0
Canonical exit: 30 Mar 2025 (T+90)
60,000 shares@ US$1.3725.6% of flowCommon StockSEC:0001562180-24-008565:1
Canonical exit: 23 Mar 2025 (T+90)
3,075 shares@ US$1.152.0% of flowCommon StockSEC:0001562180-24-008565:0
Canonical exit: 20 Mar 2025 (T+90)
25 of 177 declarations
About Prelude Therapeutics Inc
Prelude Therapeutics Inc. (NASDAQ: PRLD) is a U.S.-listed biopharmaceutical company headquartered in Wilmington, Delaware, United States. Founded in 2016, the company was built around a clear thesis: develop precision oncology medicines for areas of high unmet medical need. Its investment case is that of an early-stage biotech, where value creation depends on scientific execution, clinical data generation, and the potential to secure strategic partnerships with larger pharmaceutical companies.
Prelude’s core business is the discovery and development of novel cancer therapies. The company’s pipeline has been increasingly focused on differentiated biology, particularly highly selective KAT6A degraders and mutant-selective JAK2V617F inhibitors. In practical terms, Prelude is targeting clinically validated pathways with potentially more precise mechanisms of action, aiming to improve the balance between efficacy and safety in hard-to-treat cancers. The company has also worked on additional oncology programs, but its recent strategy indicates a sharper prioritization of the most promising assets.
Read moreShow less
From a competitive standpoint, Prelude operates in a crowded and highly innovative oncology landscape. Its competitive advantage is not scale, but specialization: a focused scientific platform, novel mechanisms, and the possibility of creating first-in-class or best-in-class therapies in selected indications. As with many small-cap biotech names, the stock is highly dependent on upcoming milestones, including regulatory filings, first-in-human studies, readouts from early clinical trials, and the company’s ability to maintain adequate funding. That makes PRLD a classic high-risk/high-reward development-stage biotech story.
Recent corporate developments have been important. In November 2025, Prelude announced an option agreement with Incyte centered on its previously undisclosed JAK2V617F mutant-selective inhibitor program, while also prioritizing the development of its first-in-class KAT6A selective degrader and pausing certain SMARCA2 programs. In early 2026, the company said its KAT6A program remained on track for an IND filing by mid-2026 and a Phase 1 start in the second half of 2026. Prelude also completed an equity financing in 2026, underscoring the capital-intensive nature of biotech development and the company’s ongoing need to fund pipeline progress.
For French-, Belgian-, and Swiss-based investors, Prelude Therapeutics is best viewed as a specialized oncology research company listed on the NASDAQ in the United States, with meaningful scientific optionality but also substantial clinical, regulatory, and financing risk.
